Peptide LSARLAF activates alpha(IIb)beta3 on resting platelets and causes resting platelet aggregate formation...

Area of Science:

• Biochemistry
• Cell Biology
• Hematology

Background:

• Platelet adhesion is crucial for hemostasis and thrombosis.
• Integrin alpha(IIb)beta3 is a key receptor mediating platelet aggregation and adhesion.
• Understanding the activation mechanisms of integrin alpha(IIb)beta3 is vital for developing anti-thrombotic therapies.

Purpose of the Study:

• To investigate the effect of a novel peptide on platelet adhesion.
• To determine if the peptide induces activation of integrin alpha(IIb)beta3 on resting platelets.
• To elucidate the mechanism by which the peptide influences platelet function.

Main Methods:

• A synthetic peptide designed to bind near the fibrinogen gamma-chain binding site of integrin alpha(IIb)beta3 was synthesized.
• Platelet adhesion assays were performed using resting platelets and various ligands (fibrinogen, fibronectin, vitronectin, von Willebrand factor).
• Platelet aggregation and shape change were monitored, and the effect of the monoclonal antibody 7E3 was assessed.

Main Results:

• The designed peptide, but not a control peptide, significantly enhanced the adhesion of resting platelets to fibrinogen and other ligands.
• Peptide-induced adhesion was independent of platelet secretion and was inhibited by the antibody 7E3.
• The peptide induced platelet aggregation without causing a shape change, indicating a specific activation pathway.

Conclusions:

• The studied peptide can activate integrin alpha(IIb)beta3 on resting platelets, promoting adhesion to multiple ligands.
• Activation appears to be mediated by a direct conformational change in the receptor, independent of secretion.
• This finding offers insights into novel mechanisms of integrin activation and potential therapeutic targets.